Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Geron Corporation (GERN)

    0.9685 -0.1815 (-15.78%)
    At close: October 28 at 4:00:00 PM EDT
    0.9700 +0.0015 (+0.15%)
    Pre-Market: 7:41:39 AM EDT
    Trade Geron on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for GERN

    What's happening with GERN?

    20m ago     Powered by Yahoo Scout

    Geron discontinued the Phase 3 IMpactMF trial after an independent Data Monitoring Committee determined that imetelstat was unlikely to improve overall survival. The company is shifting attention toward RYTELO commercialization, while third-quarter results are scheduled for November 4, 2026.

    Powered by Yahoo Scout
    • Previous Close 1.1500
    • Open 1.0150
    • Bid 0.8343 x 100
    • Ask 1.1000 x 100
    • Day's Range 0.8400 - 1.0500
    • 52 Week Range 0.8400 - 2.0100
    • Volume 81,673,530
    • Avg. Volume 11,274,553
    • Market Cap (intraday) 622.236M
    • Beta (5Y Monthly) 0.61
    • PE Ratio (TTM) --
    • EPS (TTM) -0.1100
    • Earnings Date Nov 4, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 4.25
    • Motley Fool Rating Bearish

    Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

    www.geron.com

    258

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Geron Corporation

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    GERN
    26.63%
    S&P 500 (^GSPC)
    13.13%

    1-Year Return

    GERN
    24.34%
    S&P 500 (^GSPC)
    12.38%

    3-Year Return

    GERN
    45.89%
    S&P 500 (^GSPC)
    88.08%

    5-Year Return

    GERN
    38.31%
    S&P 500 (^GSPC)
    68.48%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 57.48M
    Earnings -16.68M
    Profit Margin -29.02%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -20M
    0
    20M
    40M
    -60.0%
    -40.0%
    -20.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    3.00
    4.25 Average
    0.9685 Current
    6.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/28/2026
    Analyst Needham
    Rating Action Maintains
    Rating Buy
    Price Action Lowers
    Price Target 4 -> 2.5
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -33.05%

    • Return on Assets (ttm)

      -4.11%

    • Return on Equity (ttm)

      -28.28%

    • Revenue (ttm)

      204.56M

    • Net Income Avi to Common (ttm)

      -67.61M

    • Diluted EPS (ttm)

      -0.1100

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      300.85M

    • Total Debt/Equity (mrq)

      55.87%

    • Levered Free Cash Flow (ttm)

      -78.37M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    STEM
    ASTM
    AGEN
    EXEL
    INCY
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: